Highlights of this interview includes:
• FDA Fast Track Designation for Bile Duct Cancer granted for CF33-hNIS (VAXINIA) MAST Clinical Program;
• FDA’s Fast Track Designation for CF33-hNIS (VAXINIA) offers closer cooperation with the FDA to expedite the MAST clinical program and subsequent potential approval process; and
• Fast Track provides eligibility for Accelerated Approval and Priority Review
Imugene will utilise the Fast Track designation to work with the FDA on advancing this important drug program towards patients on an accelerated timeline.
Learn more: imugene.com
#VAXINIA #CF33 #OncolyticVirus
